--- title: "PetVivo Holdings (PETV) stock: news and investor profile" url: "https://aibio.space/companies/petvivo/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "PetVivo Holdings, Inc. (OTC: PETV), United States. Listing facts, related biotech companies and news on aibio.space." --- PETV PetVivo Holdings, Inc. OTC · United States # PetVivo Holdings (PETV) news PetVivo Holdings, Inc. is a public biotech or pharmaceutical company listed on OTC under the ticker PETV, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. ## Latest PetVivo Holdings news We have not published a story on PetVivo Holdings yet. When there is news, it will appear here. ## PetVivo Holdings at a glance - **Ticker**: PETV - **Listing**: OTC - **Country**: United States - **Cash, Dec 31, 2024**: $28,891 ### Related companies - [PyroGenesis Canada](https://aibio.space/companies/pyrogenesis-canada/) OTC: PYRGF - [BOSTON SCIENTIFIC CORP](https://aibio.space/companies/boston-scientific/) NYSE: BSX - [Inogen](https://aibio.space/companies/inogen/) NASDAQ: INGN - [Freenome](https://aibio.space/companies/freenome/) NASDAQ: FRNM - [CANNAPHARMARX, INC.](https://aibio.space/companies/cannapharmarx/) OTC: CPMD - [METTLER TOLEDO INTERNATIONAL INC/](https://aibio.space/companies/mettler-toledo-international/) NYSE: MTD - [OmniAb](https://aibio.space/companies/omniab/) NASDAQ: OABI - [Glass House Brands](https://aibio.space/companies/glass-house-brands/) NYSE: GLAS ### Also on OTC - [Enzolytics](https://aibio.space/companies/enzolytics/) ENZC - [EASTGATE BIOTECH CORP](https://aibio.space/companies/eastgate-biotech/) ETBI - [PONIARD PHARMACEUT](https://aibio.space/companies/poniard-pharmaceut/) PARD - [TRAFALGAR INTERNATIONAL, INC.](https://aibio.space/companies/trafalgar-international-gcand/) GCAND - [Evelo Biosciences](https://aibio.space/companies/evelo-biosciences/) EVLO - [Vaxxinity](https://aibio.space/companies/vaxxinity/) VAXX ## What PetVivo Holdings does PetVivo Holdings, Inc. is an emerging biomedical device company focused on manufacturing, commercializing and licensing innovative medical devices and therapeutics for animals. It is primarily engaged in veterinary products to treat or manage afflictions of companion animals such as cats, dogs and horses, and it reports a pipeline of seventeen products for the treatment of animals and humans. Most of its technology was developed for human biomedical applications. Its lead product, Spryng with OsteoCushion Technology, is a veterinarian-administered intra-articular injection for lameness and joint afflictions such as osteoarthritis in dogs and horses. The company describes Spryng as a bio-integrative scaffold made of collagen, elastin and heparin particles that mimic cartilage, and says it has elicited minimal adverse side effects in dogs and horses. Osteoarthritis is estimated to affect approximately 14 million dogs and 1 million horses in an $11 billion companion animal veterinary care and product sales market. The company commenced sales of Spryng in the second quarter of fiscal 2022 and appointed MWI as its distributor in the United States on an exclusive basis for two years, transitioning to non-exclusive thereafter. | Product or program | What it is | Stage | |---|---|---| | Spryng with OsteoCushion Technology | Veterinary intra-articular injection for lameness and osteoarthritis in dogs and horses | commercialization began in fiscal 2022 (second quarter) | Summarised from the company's [10-K filed Jun 29, 2026](https://www.sec.gov/Archives/edgar/data/1512922/000149315226031136/form10-k.htm). ## PetVivo Holdings annual financials | Line | FY ended Mar 31, 2026 | FY ended Mar 31, 2025 | |---|---|---| | Research and development | [$1.4 million](https://www.sec.gov/Archives/edgar/data/1512922/000149315226031136/) | [$1.6 million](https://www.sec.gov/Archives/edgar/data/1512922/000149315226031136/) | | Net income (loss) | [-$10.5 million](https://www.sec.gov/Archives/edgar/data/1512922/000149315226031136/) | [-$8.4 million](https://www.sec.gov/Archives/edgar/data/1512922/000149315226031136/) | | Cash from operations | [-$6.1 million](https://www.sec.gov/Archives/edgar/data/1512922/000149315226031136/) | [-$5.3 million](https://www.sec.gov/Archives/edgar/data/1512922/000149315226031136/) | | Short-term investments | [$150,000](https://www.sec.gov/Archives/edgar/data/1512922/000149315226031136/) | [$150,000](https://www.sec.gov/Archives/edgar/data/1512922/000149315226031136/) | Latest balance sheet, Dec 31, 2024 (10-Q): cash and equivalents $28,891. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about PetVivo Holdings What is the ticker symbol of PetVivo Holdings? PetVivo Holdings, Inc. trades under the ticker PETV on OTC. Where is PetVivo Holdings listed? PetVivo Holdings, Inc. is listed on OTC. Which country or territory is PetVivo Holdings listed under? Our directory records PetVivo Holdings, Inc. under United States. Does aibio.space cover PetVivo Holdings? aibio.space lists PetVivo Holdings, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. What does PetVivo Holdings develop? PetVivo Holdings, Inc. is an emerging biomedical device company focused on manufacturing, commercializing and licensing innovative medical devices and therapeutics for animals. It is primarily engaged in veterinary products to treat or manage afflictions of companion animals such as cats, dogs and horses, and it reports a pipeline of seventeen products for the treatment of animals and humans. What is Spryng with OsteoCushion Technology from PetVivo Holdings? Spryng with OsteoCushion Technology: Veterinary intra-articular injection for lameness and osteoarthritis in dogs and horses Stage: commercialization began in fiscal 2022 (second quarter). Is PetVivo Holdings profitable? PetVivo Holdings, Inc. reported a net loss of $10.5 million for the fiscal year ended Mar 31, 2026, and used $6.1 million of cash in operations, per its annual report to the SEC. How much does PetVivo Holdings spend on research and development? $1.4 million in the fiscal year ended Mar 31, 2026, per its annual report. How much cash does PetVivo Holdings have? $28,891 in cash at Dec 31, 2024, per its 10-Q. ## Investor discussion: PetVivo Holdings Members talk about PetVivo Holdings (PETV). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at PetVivo Holdings, newest first. Each line links the filing it comes from. 1. 2026-07-29 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1512922/000149315226035053/ex99-1.htm) 2. 2026-07-27 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1512922/000149315226034762/form8-k.htm) 3. 2026-06-25 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1512922/000149315226030193/ex99-1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open OTC:PETV on TradingView](https://www.tradingview.com/symbols/OTC-PETV/). ## Listing details PetVivo Holdings, Inc. is a public biotech or pharmaceutical company listed on OTC under the ticker PETV, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: PetVivo Holdings, Inc. - **Ticker**: PETV - **Listing**: OTC - **Country or territory**: United States Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/petvivo/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "PetVivo Holdings (PETV) stock: news and investor profile", 2026-10-31, https://aibio.space/companies/petvivo/